Stock Events

Stock Events

Novabay Pharmaceuticals

0

95

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Dividend Payment

Dividend Payment

Dividends

0%Dividend Yield

Sep 25

€0.68

Jul 6

€0.19

Oct 5

€0.19

Jul 5

€0.18

Apr 5

€0.18

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

N/A

1Y Growth

N/A

Earnings

6AugExpected

Q1 2026

Next

-0.86

-0.73

-0.61

-0.48

Expected EPS

-0.48334000000000005

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B9PA.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Ocular Therapeutix

Ocular Therapeutix focuses on developing treatments for eye diseases, directly competing with Novabay's eye care products.

National Vision

National Vision Holdings operates in the eye care market, offering products that can be seen as alternatives to Novabay's offerings.

Alcon specializes in eye care products, including surgical, vision care, and ophthalmic pharmaceuticals, competing across several of Novabay's key areas.

Johnson & Johnson

Johnson & Johnson, through its Vision Care division, competes in the eye health sector, offering products that rival Novabay's.

Pfizer has a broad range of healthcare products, including treatments for eye conditions that compete with Novabay's pharmaceuticals.

Novartis offers a wide range of healthcare products, including ophthalmic solutions that compete with Novabay's eye care products.

Bausch Health Companies

Bausch Health Companies, through its eye health division, directly competes with Novabay in the ophthalmology and optometry markets.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is involved in developing treatments for eye diseases, offering products that compete with Novabay's portfolio.

AbbVie, having acquired Allergan, competes in the eye care sector with a portfolio that includes treatments for various eye conditions, challenging Novabay's market share.

About

Stablecoin Development Corp. specializes in manufacturing and distributing eye and skin health solutions that have undergone rigorous scientific development and proven efficacy in clinical settings. Their product portfolio features prominent brands such as Avenova, NeutroPhase, and DERMAdoctor. This enterprise was established on January 19, 2000, and its main office is situated in Emeryville, California.

Show more...

CEO

Mr. Michael Kazley

Employees

4

Country

United States

ISIN

US66987P2011

Listings

0 Comments

Share your thoughts

FAQ

What is Novabay Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Novabay Pharmaceuticals stocks are traded under the ticker B9PA.STU.

When is the next Novabay Pharmaceuticals earnings date?▼

Novabay Pharmaceuticals is going to release the next earnings report on August 06, 2026.

Does Novabay Pharmaceuticals pay dividends?▼

Yes, B9PA.STU dividends are paid annual. The last dividend per share was 0.68 EUR. As of today, Dividend Yield (FWD)% is 0%.

How many employees does Novabay Pharmaceuticals have?▼

As of July 24, 2026, the company has 4 employees.

In which sector is Novabay Pharmaceuticals located?▼

Novabay Pharmaceuticals operates in the Other sector.

When did Novabay Pharmaceuticals complete a stock split?▼

The last stock split for Novabay Pharmaceuticals was on May 31, 2024 with a ratio of 1:35.

Where is Novabay Pharmaceuticals headquartered?▼

Novabay Pharmaceuticals is headquartered in EmeryVille, United States.